Credit Suisse Ag Cti Biopharma Corp Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$4.2 - $6.01 $64,499 - $92,295	15,357 Added 20.72%	89,490 $375,000
Q4 2022 Feb 13, 2023	BUY	$4.45 - $6.17 $327,346 - $453,871	73,561 Added 12860.31%	74,133 $445,000
Q3 2022 Nov 10, 2022	BUY	$5.36 - $7.43 $2,819 - $3,908	526 Added 1143.48%	572 $3,000
Q2 2022 Aug 12, 2022	BUY	$3.55 - $6.27 $163 - $288	46 New	46 $0
Q2 2021 Aug 16, 2021	SELL	$2.16 - $2.62 $30,492 - $36,986	-14,117 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$2.68 - $3.8 $37,833 - $53,644	14,117 New	14,117 $41,000
Q3 2019 Nov 12, 2019	SELL	$0.64 - $0.92 $8,031 - $11,545	-12,549 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$0.8 - $1.03 $11,008 - $14,173	-13,761 Reduced 52.3%	12,549 $11,000
Q1 2019 May 14, 2019	BUY	$0.9 - $1.37 $23,679 - $36,044	26,310 New	26,310 $26,000
Q3 2018 Nov 13, 2018	SELL	$1.72 - $5.24 $38,240 - $116,500	-22,233 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.81 - $5.26 $42,454 - $58,612	11,143 Added 100.48%	22,233 $110,000
Q1 2018 May 15, 2018	BUY	$2.7 - $4.06 $29,943 - $45,025	11,090 New	11,090 $43,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.